What is the recommended evaluation and management for a patient with compensated liver disease?

Evaluation and Management of Compensated Advanced Chronic Liver Disease

Patients with compensated advanced chronic liver disease (cACLD) require systematic risk stratification using non-invasive tests to identify clinically significant portal hypertension (CSPH), followed by targeted interventions including etiological therapy, non-selective beta-blockers for those with CSPH, and surveillance for hepatocellular carcinoma and varices. 1

Initial Diagnostic Evaluation

Defining cACLD

• cACLD encompasses severe fibrosis (F3) and compensated cirrhosis, representing a continuum that is often clinically indistinguishable in asymptomatic patients 2
• Liver stiffness measurement (LSM) by transient elastography provides the primary diagnostic framework:
  • LSM <10 kPa rules out cACLD 2
  • LSM 10-15 kPa is suggestive of cACLD but requires confirmatory testing 2
  • LSM ≥15 kPa is highly suggestive of cACLD 2
• Alternative blood-based screening using FIB-4 ≥1.75 identifies patients at risk for cACLD with excellent accuracy for predicting hepatic decompensation (AUROC 0.914) 3

Risk Stratification for Portal Hypertension

Portal pressure ≥10 mmHg defines CSPH as the critical threshold from which decompensating events may occur. 1

Non-invasive identification of CSPH:

• Von Willebrand factor/platelet count ratio (VITRO) demonstrates excellent diagnostic performance (AUROC 0.889) for CSPH 3
  • VITRO <1.0 rules out CSPH (100% sensitivity) 3
  • VITRO ≥2.5 rules in CSPH (92.4% specificity) 3
• Spleen stiffness measurement (SSM) using the 100-Hz VCTE module predicts liver decompensation with good accuracy (AUROC 0.823), with SSM ≥50 kPa indicating significantly increased risk 4
• LSM by transient elastography accurately predicts both decompensation (C-index 0.85) and mortality (C-index 0.74) 5

Surveillance Protocols

Variceal Screening

Upon first diagnosis of cACLD, perform upper endoscopy to assess for esophageal varices and bleeding risk. 2

• The 1-year incidence of variceal bleeding is approximately 12% overall (5% for small varices, 15% for large varices) 2
• Endoscopic surveillance intervals 2:
  • Patients without varices: repeat endoscopy every 2-3 years
  • Patients with small varices: repeat every 2-3 years, with shorter intervals for alcoholic cirrhosis or decompensated disease
  • Small varices progress to large varices at 12% per year and 25% at 2 years 2

Note on Baveno criteria: While Baveno VI criteria (LSM <20 kPa and platelets >150×10⁹/L) can avoid endoscopic surveillance in very low-risk patients, the Korean guidelines suggest this may not be necessary in settings with easy endoscopy access 2

Hepatocellular Carcinoma Surveillance

Perform liver ultrasound every 6 months for HCC surveillance, as the annual risk of malignant transformation ranges from 2-8% depending on etiology 6

Therapeutic Interventions

Etiological Therapy

Treating the underlying liver disease is paramount to prevent progression and potentially achieve cirrhosis regression. 1

• Aetiological therapies can prevent disease progression and even achieve regression of cirrhosis 1
• In alcohol-related liver disease specifically, LSM changes during monitoring have strong prognostic value 5:
  • "cACLD decreasers" (follow-up LSM <10 kPa or <20 kPa with ≥20% decrease) have significantly better outcomes 5
  • "cACLD increasers" (LSM increase ≥20%) have 4.39-fold higher risk of decompensation and 3.22-fold higher mortality risk 5

Primary Prophylaxis for Variceal Bleeding

For patients with cACLD and CSPH, non-selective beta-blockers effectively prevent decompensation, primarily by reducing ascites risk. 1

• Propranolol or carvedilol are the recommended non-selective beta-blockers 6
• Endoscopic band ligation serves as an alternative primary prophylaxis option based on risk stratification 6
• The choice between pharmacological and endoscopic therapy depends on variceal size, red wale marks, and patient-specific factors 2

Monitoring Strategy

Repeat LSM after a median of 2 years to assess disease trajectory and refine prognosis. 5

• Baseline LSM, follow-up LSM, and LSM changes all independently predict outcomes 5
• Follow-up LSM provides the highest accuracy for decompensation prediction (C-index 0.89) 5
• SSM can be incorporated for enhanced risk stratification, particularly when SSM ≥50 kPa 4

Additional Preventive Measures

Infection Prevention

• Verify vaccination status and administer missing vaccinations 6
• Routine antibiotic prophylaxis remains controversial due to insufficient evidence and antimicrobial resistance concerns 6

Metabolic Bone Disease and Sarcopenia

• Counsel patients on osteoporosis prevention and consider pharmacotherapy 6
• Address muscle wasting through nutritional counseling and potential drug therapy 6

Critical Prognostic Thresholds

The transition from compensated to decompensated disease dramatically increases 1-year mortality from 1-3.4% to 20-57%. 6

• Approximately 15% of patients with cACLD decompensate annually despite prophylactic measures 6
• When decompensation occurs, particularly with MELD >15, liver transplantation evaluation becomes essential 6
• FIB-4 <1.75 identifies patients with negligible 5-year decompensation risk (0.3%), while FIB-4 ≥1.75 indicates 7.6% 5-year cumulative incidence 3

Important Caveats

Do not use LSM cut-offs established for untreated patients to stage fibrosis after successful viral eradication (e.g., post-SVR in HCV), as LSM decreases substantially (median 28% relative decline) even when cirrhosis persists 7

MELD score remains the recommended prognostic tool for short-term mortality prediction if decompensation occurs, as most investigational markers perform similarly or worse than MELD in decompensated disease 7